Renaissance Pharma secures FDA Breakthrough Therapy Designation for daretabart in newly diagnosed high-risk neuroblastoma
FOR INVESTORS AND FINANCIAL AND BUSINESS MEDIA ONLY Renaissance Pharma secures FDA Breakthrough Therapy Designation for daretabart in newly diagnosed high-risk neuroblastoma Designation covers daretabart in combination with induction chemotherapy for first-line treatment in paediatric patients First Breakthrough Therapy Designation (BTD) for daretabart, an investigational anti-GD2 humanised monoclonal antibody Daretabart is an investigational asset and […]